Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
04/2009
04/30/2009US20090111822 1,2,3-triazole pyrrolidine derivatives as modulators of mglur5
04/30/2009US20090111821 Amino 1,2,4-triazole derivatives as modulators of mglur5
04/30/2009US20090111820 Fused pyrrolidine 1,2,4-triazole derivatives as modulators of mglur5
04/30/2009US20090111819 New pyridazin-3(2h)-one derivatives
04/30/2009US20090111818 Combinations of Eszopiclone and O-Desmethylvenlafaxine, and Methods of Treatment of Menopause and Mood, Anxiety, and Cognitive Disorders
04/30/2009US20090111817 Combinations of Eszopiclone and an Antidepressant
04/30/2009US20090111816 Polycyclic aryl substituted triazoles and polycyclic heteroaryl substituted triazoles useful as axl inhibitors
04/30/2009US20090111814 Feminine anti-itch gel
04/30/2009US20090111813 Dialkylamino alkyl esters of pivagabine as medicaments for the treatment of central nervous system disorders
04/30/2009US20090111812 Methods for treating inflammatory disorders
04/30/2009US20090111811 1,2,4-triazole carboxylic acid derivatives as modulators of mglur5
04/30/2009US20090111810 Substituted pyrimidine-5-carboxamide and 5-carboxylic ester kinase inhibitors
04/30/2009US20090111809 Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
04/30/2009US20090111808 Novel histamine h3-receptor ligands and their therapeutic applications
04/30/2009US20090111807 Novel 1,2,3,4-Tetrahydroquinoxaline Derivative Having Glucocorticoid Receptor Binding Activity
04/30/2009US20090111806 Azaquinolone based compounds exhibiting prolyl hydroxylase Inhibitory activity, compositions, and uses thereof
04/30/2009US20090111805 Bicyclic heteroaromatic derivatives useful as anticancer agents
04/30/2009US20090111804 ARYLINDENOPYRIMIDINES AND THEIR USE AS ADENOSINE A2a
04/30/2009US20090111803 novel hydantoin derivatives to inhibit matrix metalloproteinases (MMPs), a disintegrin and metalloproteases (ADAMs) and/or tumor necrosis factor alpha converting enzyme (TACE) and in so doing prevent the release of tumor necrosis factor alpha (TNF- alpha ); autoimmune diseases; side effect reduction
04/30/2009US20090111802 Cyclocarbamate derivatives as progesterone receptor modulators
04/30/2009US20090111801 Substituted pyrazinone derivatives for use as a medicine
04/30/2009US20090111800 Cyclohexylpyrazole-lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
04/30/2009US20090111799 Anti-infective agents against intracellular pathogens
04/30/2009US20090111798 N-{3-[1-(4-Fluoro-benzyl)-4-hydroxy-2-oxo-2,4a,5,6,7,7a-hexahydro-1H-[1]pyrindin-3-yl]-1,1-dioxo-1,4-dihydro-1 lambda 6-benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide;hepatitis C viral infections; hepatitis C NS5B polymerase inhibitors; enzyme inhibitors; viricides; side-effect reduction
04/30/2009US20090111797 (R)-1-(3,4-dibromo-benzyl)-2-[4-(1-methyl-piperidin-4-yl)-piperazin-1-yl]-2-oxo-ethyl4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate, for example; treatment of headaches, particularly migraine or cluster headaches
04/30/2009US20090111796 7-membered ring compound and method of production and pharmaceutical application thereof
04/30/2009US20090111795 Multimers of Heterocyclic Compounds and Their Use
04/30/2009US20090111794 Aryl-substituted bridged or fused diamines as modulators of leukotriene A4 hydrolase
04/30/2009US20090111793 Hydroxyalkanoylaminolactams and related structures as inhibitors of a beta protein production
04/30/2009US20090111792 Injectable capsaicin with tricyclic antidepressant adjunctive agent
04/30/2009US20090111791 Soluble Epoxide Hydrolase Inhibitors and Methods of Using Same
04/30/2009US20090111790 Heteroaryl benzamide derivatives for use as glk activators in the treatment of diabetes
04/30/2009US20090111789 Chiral cis-imidazolines
04/30/2009US20090111788 Antibiotic compositions of modified release and process of production thereof
04/30/2009US20090111787 Polymer blends for drug delivery stent matrix with improved thermal stability
04/30/2009US20090111786 Compounds that Prevent Macrophage Apoptosis and Uses Thereof
04/30/2009US20090111785 Combinations comprising antimuscarinic agents and corticosteroids
04/30/2009US20090111784 Medication against breast cancer and related diseases
04/30/2009US20090111783 Dermatological compositions comprising hydroquinone, fluocinolone acetonide and tretinoin for treating the hyperpigmentation of pathological scars
04/30/2009US20090111782 Composition and methods relating to glucocorticoid receptor-alpha and peroxisome proliferator-activated receptors
04/30/2009US20090111781 Use of Cymipristone Type Compounds in Aids Treatment
04/30/2009US20090111780 Compositions and methods for treatment of ear canal infection and inflammation
04/30/2009US20090111779 Methods of use for 2,5-dihydroxybenzene sulfonic acid compounds for the treatment of cancer, rosacea and psoriasis
04/30/2009US20090111778 2-Keto-Oxazoles as Modulators of Fatty Acid Amide Hydrolase
04/30/2009US20090111777 Jelly Composition
04/30/2009US20090111776 Novel tetracycline derivatives as antibacterial agents
04/30/2009US20090111775 Molecular transporter compositions comprising dendrimeric oligoguanidine with a tri-functional core that facilitates delivery into cells in vivo
04/30/2009US20090111774 Pmea lipid conjugates
04/30/2009US20090111773 Compositions and methods of using lamellar bodies for modifying linear biological macromolecules
04/30/2009US20090111772 Formulation of quinazoline based egfr inhibitors containing a zinc binding moiety
04/30/2009US20090111771 Inhibition of cathepsin k activity and the treatment and prevention of disease
04/30/2009US20090111770 Pharmaceutical Composition Free From Dexpanthenol, Calcium Ions, and Phosphate and Use of Calcium Chelating Agent and Ophthalmologically Compatible Viscosity Regulator
04/30/2009US20090111769 Antithrombotic Compound
04/30/2009US20090111768 Regulators of protein misfolding and neuroprotection and methods of use
04/30/2009US20090111767 Modulation of insulin like growth factor i receptor expression
04/30/2009US20090111766 Raav vector-based compositions and methods for the prevention and treatment of mammalian diseases
04/30/2009US20090111765 Compositions and methods for immunostimulatory rna oligonucleotides
04/30/2009US20090111764 Mitochondrial selection
04/30/2009US20090111763 Loadable polymeric particles for bone augmentation and methods of preparing and using the same
04/30/2009US20090111762 Method of diagnosing and treating cancer using b-catenin splice variants
04/30/2009US20090111761 Prostaglandin Analog Compositions And Methods To Treat Epithelial-Related Conditions
04/30/2009US20090111760 Macrolone compounds
04/30/2009US20090111754 Selective Inhibitors of Nuclear Factor KappaB Activation and Uses Thereof
04/30/2009US20090111744 Human Growth Gene and Short Stature Gene Region
04/30/2009US20090111742 Use of fgf-21 and thiazolidinedione for treating type 2 diabetes
04/30/2009US20090111733 Par-4 related methods and compositions
04/30/2009US20090111732 Gelling Hydrophobic Injectable Polymer Compositions
04/30/2009US20090111731 Novel topical application agents against mimic and age-related wrinkles
04/30/2009US20090111183 Ketone Ligands for Modulating the Expression of Exogenous Genes Via An Ecdysone Receptor Complex
04/30/2009US20090110760 Lipometabolism improver containing pine bark extract
04/30/2009US20090110755 Compositions and Methods for Preventing Migraines
04/30/2009US20090110753 Enzyme-cleavable prodrug compounds
04/30/2009US20090110746 New class of therapeutics that enhance small modecule diffusion
04/30/2009US20090110745 Over-the-counter vitamin/nutriceutical formulation that provides neuroprotection and maintains or improves cognitive performance in alzheimer's disease and normal aging
04/30/2009US20090110740 Materials and Methods for Modulating Metabolism
04/30/2009US20090110739 Targeted cancer chemotherapy using synthetic nanoparticles
04/30/2009US20090110737 Orally Disintegrating Powder Comprising Cilostazol and Mannitol
04/30/2009US20090110736 Alloplastic injectable dermal filler and methods of use thereof
04/30/2009US20090110735 Controlled release formulations
04/30/2009US20090110734 Quaternised ammonium cyclodextrin compounds
04/30/2009US20090110732 Bioresorbable composition for repairing skeletal tissue
04/30/2009US20090110731 Loadable Polymeric Microparticles for Therapeutic Use in Alopecia and Methods of Preparing and Using the Same
04/30/2009US20090110729 Solid oral compositions based on s-adenosyl methionine and/or nadh and process for obtaining them
04/30/2009US20090110728 Zero-Order Modified Release Solid Dosage Forms
04/30/2009US20090110727 Extended release compositions of proton pump inhibitors
04/30/2009US20090110724 Compositions and methods for treatment of pain
04/30/2009US20090110722 Composition
04/30/2009US20090110720 Use of compounds for the prevention of drug-induced cell toxicity
04/30/2009US20090110719 Polyamine modified particles
04/30/2009US20090110718 Derivatives of tiacumicin B as anti-cancer agents
04/30/2009US20090110717 Transmucosal composition
04/30/2009US20090110713 Biodegradable polymeric materials providing controlled release of hydrophobic drugs from implantable devices
04/30/2009US20090110711 Implantable device having a slow dissolving polymer
04/30/2009US20090110709 Composition comprising an effective amount of a polyphenolic compound, in particular, ellagic acid and/or tannic acid, and a peptide for protection against degradation of cutaneous elastic fibers by elastolytic enzymes; for treating aging or damaged skin
04/30/2009US20090110694 Anti-Inflammatory Proteins and Improved Vaccines
04/30/2009US20090110690 Hiv Gp120 Crystal Structure and Its Use to Identify Immunogens
04/30/2009US20090110684 Neutralizing monoclonal antibodies to respiratory syncytial virus
04/30/2009US20090110678 Receptor antagonists for treatment of metastatic bone cancer
04/30/2009US20090110673 Methods of reducing cell death following hypoxia / reoxygenation
04/30/2009US20090110671 Agent for enhanching the production of collagen and it's use